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Thyroid disorders are well known to be associated with cardiovascular diseases. Some
studies have shown that the negative effects of thyroid disorders are partially reversible
after adequate treatment. The aim of this analysis was to assess the risk of incident ische-
mic cerebrovascular diseases in study participants treated for thyroid dysfunctions in a pop-
ulation-based cohort study.
Methods
For the presented analyses data from 8564 male and 8714 female individuals aged 25 to 74
years of the MONICA/KORA cohort were used (median follow-up 14.0 years). A combined
binary variable “thyroid disorder” (TDC) was created utilizing data on self-reported physi-
cian-treated thyroid disorders and information about medication use. To examine the asso-
ciation between TDC and incident ischemic cerebrovascular events, we performed multiple
adjusted Cox proportional hazard regression models and calculated hazard ratios and cor-
responding 95% confidence intervals (HR, 95%CI).
Results
During follow-up between 1984 and 2008/2009, 514 incident fatal and non-fatal ischemic
cerebrovascular events occurred in men and 323 in women. At baseline, 3.5% of men and
15.6% of women reported TDC. In the fully adjusted model, males who reported TDC had a
significantly reduced risk of ischemic cerebrovascular events (HR = 0.52, 95%CI = 0.29–
0.92). A similar result was obtained in men, when we utilized information on thyroid hor-
mones use only. For the total study population and for women with TDC we found no associ-
ation with ischemic cerebrovascular events.
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Conclusions
In our longitudinal analyses subjects with treated thyroid diseases had no increased risk of
incident ischemic cerebrovascular events. Surprisingly in males, even a significantly
reduced risk of incident ischemic cerebrovascular events was found, a result that deserves
further clarification.
Introduction
Thyroid disorders are common diseases worldwide [1] and are known to be associated with
several cardiovascular disorders [2–4]. The prevalence of thyroid diseases depends on age, gen-
der, geographical factors, and iodine intake [5]. Hypothyroidism is the most frequent patholog-
ical condition with abnormally elevated thyroid stimulating hormone (TSH) levels; depending
on the plasma concentration of thyroid hormones a distinction can be made between overt or
subclinical hypothyroidism [6, 7]. In patients with hyperthyroidism tissues are exposed to TSH
concentrations below the reference range in the subclinical as well as overt status; the overt sta-
tus is additionally characterized by elevated production of thyroid hormones [6].
Cerebrovascular diseases are still one of the major causes of mortality worldwide [8] and
they go along with many years of life lost and years lived with disabilities [9, 10]. Rather limited
information exists about the association between thyroid disorders and incident cerebrovascu-
lar diseases [11–14], whereas several studies predominantly indicate a positive association
between thyroid disorders and an increased risk of ischemic heart disease [3, 14–16]. However,
little comparable information is available on whether this holds true for cerebrovascular disease
as well [12].
Looking at studies with participants suffering from thyroid disorders and only partly
treated, a more recent prospective study reported that hyperthyroidism was associated with an
increased risk of stroke [7] whereas two larger studies reported no association between hyper-
thyroidism and stroke incidence [17, 18]. For participants of the First National Health and
Nutrition Survey suffering from hypothyroidism an elevated risk for all strokes and ischemic
stroke was observed [18]. Contrary to these results, a registry-based study was unable to detect
a relation between hypothyroidism and stroke [17].
With the focus only on patients treated for thyroid disorders, a study based on clinical regis-
try data could not demonstrate a relation between hyperthyroidism and cerebrovascular dis-
ease, but reported an increased risk of cerebrovascular disease in patients treated for
hypothyroidism compared to the general population [14].
Thus, the information about the association between thyroid disorders and cerebrovascular
diseases is limited and conflicting. The aim of this study, therefore, was to assess the risk of
incident ischemic cerebrovascular diseases in study participants with thyroid dysfunctions in a
prospective population-based study, comparing treated participants vs. non-treated persons
from the general population.
Materials and Methods
Study design and participants
The presented analyses are based on the MONICA (MONitoring of Trends and Determinants
in CArdiovascular Disease)/KORA (Cooperative Health Research in the Region of Augsburg)
studies. At baseline, four independent study populations were recruited based on a random
sample (1984/85 (S1), 1989/90 (S2), 1994/95 (S3), and 1999/2001 (S4) in the city of Augsburg
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and two surrounding counties with the aim to examine the distribution and time trends of car-
diovascular risk factors [19, 20]. The response decreased gradually over the years from 79% in
S1 to 65% in S4 [21, 22]. The age range of the participants was between 25 and 64 years at
study entry in S1 and between 25 and 74 years in S2-S4. Subjects from all four surveys were
prospectively followed up within the KORA framework until 2008/2009 [19, 23]. May 12,
2015). Of the initially included 17604 (8769 male, 8835 female) individuals in our dataset 326
persons were excluded due to a history of (any type of) stroke (n = 209) at baseline and/or an
incident hemorrhagic cerebrovascular event during the follow-up (n = 129).
In all surveys, extensive baseline information was collected. More detailed data about study
design, recruitment methods and data collection have been published previously [19].
Approval from the local ethics committee (Bayerische Landesärztekammer) was received.
In accordance with institutional requirements and the Declaration of Helsinki all participants
provided written informed consent after full explanation of the purpose and nature of all pro-
cedures used.
Data collection procedures
Baseline status and risk factors such as demographic and sociodemographic variables, lifestyle
factors, medication use and medical history were collected through standardized computer
assisted interviews of participants by trained medical staff. In addition, participants underwent
extensive physical examinations and health status assessment including body height and body
weight. Furthermore, non-fasting blood samples were drawn while sitting. Details about the
measurement procedures were described elsewhere [19, 20].
Measures
Thyroid disorders. In epidemiologic studies, different information sources can be used to
characterize subjects as euthyroid or suffering from thyroid dysfunction. The analysis of serum
levels of TSH and thyroxine (T4) is frequently used to assess the thyroid function. A non-inva-
sive option is to ask people about their medical diagnoses or assess and evaluate their medica-
tion use. Following this approach, it is possible to assess data about the longer-term health
status and take into account current treatment. In our analyses, multiple non-invasive informa-
tion sources were used to define four variables as proxies for treated thyroid disorders. During
the medical face-to-face interview questions were asked if the study participants suffered from
physician-treated thyroid disorders during the last 12 months and if they received treatment.
In addition to the medical questions, all medications taken by the participant during the past 7
days were recorded including dosage and administration form. Utilizing the Anatomical Ther-
apeutic Chemical (ATC) classification system from the WHO Collaborating Center for Drug
Statistics Methodology allows a comparison of drug consumption at international level [24]
and avoids false positive disease reports. The use of thyroid hormones is a common therapy
and a clear indication of a current thyroid disorder, such as hypothyroidism and struma [25,
26]. Furthermore, they are prescribed regularly after struma/thyroidectomy [25, 26]. Beside
radioactive iodine and surgery, thyreostatic medication is one of the main treatment options
for hyperthyroidism [25–27]. The type of treatment depends on factors such as cause and
severity of the disease, age of the patients, and the presence of coexisting conditions [25–27].
We utilized the questions about treated thyroid disorders in the last 12 months and also the
information about thyroid hormone and thyreostatic medication use to create a combined
binary variable “thyroid disorder” (TDC) (yes, no). Based solely on information from the medi-
cal anamnesis at baseline, the binary questionnaire variable “thyroid disorder” (TDQ) (yes, no)
was generated. This variable does not distinguish between hypothyroidism and
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hyperthyroidism. With the information on thyroid hormone use only we created the variable
“hypothyroidism/struma” (HOT) (yes, no) and with the information on thyreostatic medica-
tion use the variable “hyperthyroidism” (HET) (yes, no). HET could not be used for statistical
tests or multivariate analyses due to the low number of cases.
Covariates. Information about age, sex, education (< vs.> = 12 years school and profes-
sional education), smoking habits (never, former/irregular current, regular current), physical
activity (active, inactive), and alcohol consumption (g/day) was collected through standardized
computer assisted interviews and additional questionnaires. Body mass index (BMI) was calcu-
lated as weight in kilograms divided by squared height in meters. The participants completed a
self-administered, short food frequency questionnaire from which a healthy nutrition index
was built (healthy, normal, unhealthy dietary pattern).
Hypertension, myocardial infarction, diabetes mellitus, hyperuricemia, and an unfavorable
blood lipid ratio were included as covariates as they have been shown to be risk factors for car-
diovascular diseases including cerebrovascular diseases [27–30]. Arterial hypertension (yes,
no) was defined as a systolic blood pressure of>140mm Hg, and/or diastolic blood pressure of
>90mm Hg, and/or current use of antihypertensive medication, given that the persons were
aware of being hypertensive. Patient’s self-report about “in hospital treated myocardial infarc-
tions” was used for the classification of myocardial infarction (yes, no). Diabetes mellitus was
defined by the patient’s self-report of a physician diagnosed diabetes mellitus and/or current
use of antidiabetic medications [31]. Hyperuricemia was defined as blood concentrations of
uric acid exceeding 6.5 mg/dl [32]. For the statistical analyses, we computed the unfavorable
lipid ratio (total cholesterol/HDL-cholesterol) because it is a simple and powerful predictor for
coronary heart disease risk [33]. Ratios greater than 6 indicate a high risk for the onset of car-
diovascular diseases [34, 35]. Additionally, for women menopause status was assessed during
the interview and classified into three categories (postmenopausal, hormone therapy or men-
struation, premenopausal).
Outcome and follow up. The end point used in these analyses were incident fatal and
non-fatal ischemic cerebrovascular events (ICE) which include ischemic and embolic strokes,
transient ischemic attacks “TIA”, prolonged ischemic neurological deficit “PRIND”, and fur-
ther forms of ICE. These events were identified through follow-up activities which included
regular checking of the subject’s vital status (through population registries inside and outside
the study area), three postal questionnaires focusing on chronic diseases, and also follow-up
studies in which the participants were invited to the KORA study center for medical examina-
tion and a standardized interview. An ICE was defined as incident if its occurrence was
observed for the first time during the follow-up. Diagnoses were validated by autopsy reports,
death certificates, clinical records, and information from the last treating physician. The under-
lying cause of death was coded using the ninth revision of the International Classification of
diseases (ICD-9).
Statistical analyses. Baseline characteristics and additional variables, selected through lit-
erature research, were examined as median and interquartile range for continuous variables
(variables did not meet the normality assumption) and as absolute and relative frequencies for
categorical variables stratified by sex and the variables TDC and HOT. Bivariate tests for differ-
ences between participants with and without treated thyroid disorders were performed apply-
ing Wilcoxon-Mann-Whitney-tests for continuous parameters and Chi2 tests for categorical
variables to check the statistical significance. With the selected variables out of the bivariate
tests we examined the association between the three thyroid disorder variables TDC, TDQ, as
well as HOT and ICE. Cox proportional hazard regression models with days as the timescale
and calculation of hazard ratios (HR) and corresponding 95% confidence intervals (95%CI)
were performed. Time at entry was the day at baseline examination. Exit time was the day
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when either a participant was diagnosed with an ICE, died, was lost to follow-up, or was cen-
sored at the end of the follow-up period. The crude model adjusted for age, sex, and survey was
further adjusted in groups for lifestyle factors (education, BMI, alcohol consumption, smoking
habits, physical activity, and dietary patterns), and clinical risk factors (history of arterial hyper-
tension, diabetes mellitus, hyperuricemia, and unfavorable blood cholesterol ratio) until a fully
adjusted model (crude model adjusted for lifestyle factors and clinical risk factors) was obtained.
Additionally, the variable myocardial infarction (yes, no) in all participants and menopause sta-
tus at baseline in women only were tested as adjusting variable. However, both did not change
the risk estimates (data not shown) and were not included in the fully adjusted models.
To test the robustness of our models, we calculated the Cox proportional hazard regressions
without embolic strokes as part of the outcome variables. Therefore, in this sensitivity analysis
only incident ischemic strokes, TIAs/PRINDs and further undefined forms of ICE were
included as relevant outcomes. Furthermore, we tested for interactions between the thyroid
disorder variables (TDC, TDQ, as well as HOT) and sex, hypertension as well as alcohol con-
sumption. Additionally, in women interaction between thyroid disorders and menopause sta-
tus was assessed. To minimize the likelihood of reverse causal associations, we imposed a two-
year lag period between baseline data ascertainment and the onset of observation time for ICE.
All analyzed tests and regression models were also done stratified by gender.
Significance tests were 2-tailed. A p-value of less than 0.05 was considered significant. The
assumption of proportionality of hazards was assessed by visualizing the log(-log(survival)
plots of models stratified by risk factor categories. All interaction analyses were conducted by
including a cross-product term along with the main effect terms in the Cox regression models.
The statistical significance of the cross-product term was evaluated using the likelihood ratio
test between models. The log-rank test was used to test for differences in the survivor function.
For all analyses the software package SAS 9.3 (SAS Institute Inc., Cary, NC, USA) was used.
Results
In the 25- to 74-year old study population (N = 17,278) at baseline 837 ICE were identified dur-
ing the follow-up between 1984 and 2008/2009 (median follow-up time 14.0 years). In men
514 (median follow-up 13.9 years) and in women 323 (median follow-up 14.1 years) incident
ICE were registered. From all incident ischemic cerebrovascular cases 167 were fatal, 89 among
men and 78 among women.
At the baseline examination, significantly more women than men reported a treated thyroid
disorder. This applies to the questions during the medical interview as well as thyroid hormone
use or antithyroid medication use (men: TDC 3.5%, TDQ 2.9%, HOT 2.8%, HET 0.1%,
women: TDC 15.6%, TDQ 13.6%, HOT 12.3%, HET 0.4%).
The baseline characteristics stratified by sex and TDC or HOT are described in Tables 1 and
2. Similar distributions were found among the different thyroid disorder categories (TDC,
TDQ, HOT). Males and females treated for thyroid disorders were at baseline significantly
older than non-treated persons. Furthermore, hypertension and diabetes mellitus were more
common in men and women with treated thyroid disorders. The prevalence of myocardial
infarction was independent from the presence of treated thyroid disorders. Women with
treated thyroid disorders had a significantly higher BMI, a lower education and more often a
diagnosis of hyperuricemia and they were more often in a postmenopausal status. Men suffer-
ing from thyroid disorders (treated) reported to smoke less regularly or never and to eat a diet
with a healthier dietary pattern.
Among the 9 hyperthyroid men in our study population no incident ICE occurred during
follow-up; among the 38 hyperthyroid women two incident ICE were diagnosed.
Thyroid Dysfunctions and Cerebrovascular Diseases
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Table 1. Demographic, lifestyle and clinical factors by treated thyroid disorders (TDC) in men and women, KORA population S1-S4.
Men P-value Women P-value
TDC yes TDC no TDC yes TDC no












Survey 1 48 15.9 1938 23.5 0.0106f 267 19.6 1707 23.2 <0.0001f
2 81 26.8 2255 27.3 335 24.6 2019 27.5
3 89 29.5 2153 26.1 353 26.0 1923 26.2
4 84 27.8 1913 23.2 404 29.7 1704 23.2
Lifestyle factors











g/day 20.0 2.9–38.0 20.4 5.7–42.9 0.0344e 2.8 0.0–11.7 2.8 0.0–14.3 0.0076e
Education <12 years 189 62.6 5181 62.9 0.8982f 1115 82.1 5626 76.6 <0.0001f
12 years 113 37.4 3050 37.0 243 17.9 1715 23.4
Smoking habits Regular current 61 20.2 2424 29.4 0.0005f 253 18.6 1366 18.6 0.6837f
Former/ unregular 152 50.3 3352 40.7 315 23.2 1628 22.2
Never 89 29.5 2458 29.8 790 58.2 4350 59.2
Physical activity Active 118 39.1 3706 45.0 0.0402f 538 39.6 2981 40.6 0.4873f
Inactive 184 60.9 4520 54.9 820 60.4 4357 59.3
Dietary pattern Unhealthy 111 36.8 3575 43.4 0.0012f 328 24.2 1970 26.8 0.1223f
Normal 55 18.2 1785 21.7 291 21.4 1521 20.7
Healthy 136 45.0 2861 34.8 737 54.3 3843 52.3
Menopause status Postmenopausal 769 56.6 3356 45.7 <0.0001f
Hormone intake
and menstruation
31 2.3 163 2.2
Premenopausal 528 38.9 3684 50.2
Clinical factors/diseases
Hypertension Yes 149 49.3 3583 43.5 0.0455f 519 38.2 2232 30.4 <0.0001f
No 153 50.7 4649 56.5 838 61.7 5110 69.6
Diabetes mellitus Yes 20 6.6 332 4.0 0.0262f 76 5.6 224 3.0 <0.0001f
No 282 93.4 7902 96 1282 94.4 7119 96.9
Unfavorable lipid
ratiob
Yes 63 20.9 1875 22.8 0.4315f 121 8.9 521 7.1 0.0200f
No 234 77.5 6217 75.5 1203 88.6 6620 90.1
Hyperuricemiac Yes 77 25.5 2155 26.2 0.8427f 63 4.6 227 3.1 0.0040f
No 218 72.2 5940 72.1 1264 93.1 6904 94.0
Myocardial
infarction
Yes 10 3.3 234 2.8 0.6307f 12 0.9 48 0.6 0.3466f




Yes 9 3.0 0 0.0 38 2.8 0 0.0
No 293 97.0 8234 100.0 1320 97.2 7345 100.0
Thyroid hormone
use
Yes 242 80.1 0 0.0 1068 78.6 0 0.0




Yes 14 4.6 498 6.0 52 3.8 270 3.7
(Continued)
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The hazard ratios and corresponding 95% confidence intervals for the association of treated
thyroid disorder (TDC, TDQ or HOT) and ICE are given in Table 3. The results for all three
thyroid disorder variables were quite comparable. Considering the entire study population, in
the crude model, in the model adjusted for lifestyle factors as well as in the fully adjusted
model, study participants who reported a treated thyroid disorder had no change in risk for an
incident ICE in comparison to study participants without a treated thyroid disorder (fully
adjusted model: TDC, HR = 0.80, 95%CI = 0.61–1.04; TDQ, HR = 0.87, 95%CI = 0.65–1.15;
HOT, HR = 0.75, 95%CI = 0.56–1.01).
For men suffering from thyroid disorders (treated) the crude model (adjusted for age and
survey) showed a significantly reduced risk of ICE compared to men without treated thyroid
disorders. This association remained stable in the fully adjusted model. In two of the three thy-
roid disorder categories the results reached the significance level (fully adjusted model: TDC,
HR = 0.52, 95%CI = 0.29–0.92; TDQ, HR = 0.66, 95%CI = 0.37–1.17; HOT, HR = 0.49, 95%
CI = 0.26–0.92).
We did not see any statistically significant effects in the same models for women (fully
adjusted model: TDC, HR = 0.94, 95%CI = 0.37–1.17; TDQ, HR = 0.97, 95%CI = 0.37–1.17;
HOT, HR = 0.88, 95%CI = 0.37–1.17).
As demonstrated in the sensitivity analyses, embolic strokes had no relevant impact on the
association between treated thyroid disorders and the risk of ICE. The results are shown in
Table 4. None of the p-values for interaction reached the significance level.
Discussion
The main findings of this population-based, prospective study with more than 17,000 adults
was that study participants who suffered from treated thyroid disorder had no higher risk for
incident ischemic cerebrovascular events (ICE). Furthermore, a protective effect of treated
Table 1. (Continued)
Men P-value Women P-value
TDC yes TDC no TDC yes TDC no
Baseline characteristics n = 302 % n = 8259 % n = 1359 % n = 7353 %
No 276 91.4 7259 88.2 1208 89 6591 89.7
embolic strokes Yes 3 1.0 82 1.0 9 0.7 57 0.8
No 299 99 8152 99.0 1349 99.3 7288 99.2
TIA/PRIND Yes 0 0.0 122 1.5 12 0.9 61 0.8
No 290 96 7635 92.7 1248 91.9 6800 92.6








TDC, treated thyroid disorders (yes/no) based on the information on self-reported physician-treated disease and medication use; TIA/PRIND, Transient
ischaemic attack/prolonged ischaemic neurological deficit. Data are presented in n (%) or median (interquartile range).
a Median und Interquartile range.
b Total cholesterol (mg/dl)/high-density lipoprotein (mg/dl), 6 (yes), <6 (no).
c Uric acid  6.5 mg/dl.
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Table 2. Demographic, lifestyle and clinical factors by thyroid hormone use (HOT) in men and women, KORA population S1-S4.
Men P-value Women P-value
HOT yes HOT no HOT yes HOT no












Survey 1 40 16.5 1943 23.4 0.0595f 204 19.1 1768 23.1 0.0007f
2 69 28.5 2262 27.2 283 26.5 2071 27.1
3 65 26.8 2177 26.2 275 25.8 2001 26.2
4 68 28.1 1923 23.2 306 28.6 1800 23.6
Lifestyle factors











g/day 20.0 4.4–37.1 20.4 5.7–42.9 0.0538e 2.8 0.0–11.4 2.8 0.0–14.3 0.0079e
Education <12 years 152 62.8 5225 62.9 0.9641f 885 82.9 5857 76.7 <0.0001f
12 years 90 37.2 3075 37.0 183 17.1 1776 23.2
Smoking habits Regular current 48 19.8 2441 29.4 0.0003f 186 17.4 1434 18.8 0.5563f
Former/ unregular 128 53.9 3380 40.7 244 22.8 1699 22.2
Never 66 27.3 2483 29.9 638 59.7 4505 59.0
Physical activity Active 97 40.1 3728 44.9 0.1314f 423 39.6 3096 40.5 0.5409f
Inactive 145 59.9 4561 54.9 645 60.4 4532 59.3
Dietary pattern Unhealthy 88 36.4 3600 43.4 0.0007f 241 22.6 2057 26.9 0.0095f
Normal 41 16.9 1800 21.7 238 22.3 1574 20.6
Healthy 113 46.7 2884 34.7 587 55.0 3993 52.3
Menopause status Postmenopausal 633 59.3 3492 45.7 <0.0001f
Hormone intake
and menstruation
24 2.2 170 2.2
Premenopausal 390 36.5 3822 50.0
Clinical factors/ diseases
Hypertension Yes 125 51.6 3613 43.5 0.0120f 421 39.4 2331 30.5 <0.0001f
No 117 48.4 4687 56.4 646 60.5 5302 69.4
Diabetes mellitus Yes 16 6.6 337 4.1 0.0491f 68 6.4 232 3.0 <0.0001f
No 226 93.4 7967 95.9 1000 93.6 7406 96.9
Unfavorable lipid
ratiob
yes 48 19.8 1893 22.8 0.2752f 95 8.9 548 7.2 0.0460f
No 190 78.5 6269 75.5 946 88.6 6881 90.1
Hyperuricemiac Yes 64 26.4 2169 26.1 0.8808f 54 5.1 237 3.1 0.0010f
No 173 71.5 5995 72.2 988 92.5 7184 94.0
Myocardial
infarction
Yes 9 3.7 235 2.8 0.4134f 5 0.5 55 0.7 0.3507f




Yes 3 1.2 6 0.1 12 1.1 26 0.3




Yes 12 5.0 500 6.0 41 3.8 2.81 3.7
No 221 91.3 7325 88.2 952 89.1 6851 89.7
Embolic strokes Yes 3 1.2 82 1.0 9 0.8 57 0.8
(Continued)
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Table 2. (Continued)
Men P-value Women P-value
HOT yes HOT no HOT yes HOT no
Baseline characteristics n = 242 % n = 8305 % n = 1068 % n = 7640 %
No 239 98.8 8223 99.0 1059 99.2 7583 99.3
TIA/PRINDe Yes 0 0.0 122 1.4 10 0.9 63 0.8
No 233 96.3 7703 92.8 983 92.0 7069 92.5








HOT, hypothyroidism/struma (yes, no) classification based on thyroid hormone use; TIA/PRIND, Transient ischaemic attack/prolonged ischaemic
neurological deficit.
Data are presented in n (%) or median (interquartile range).
a Median und Interquartile range.
b Total cholesterol (mg/dl)/high-density lipoprotein (mg/dl), 6 (yes), <6 (no).
c Uric acid  6.5 mg/dl





Table 3. Gender specific and overall hazard ratios (HR) and 95%CI for developing an ischemic cerebrovascular event according to thyroid disor-
ders at baseline.
Crude modela Lifestyle modelb Lifestyle and clinical risk
factor modelc
HR (95%CI) HR (95%CI) HR (95%CI)
TDC ne
Totald 15,611 0.84 (0.65–1.09) 0.83 (0.64–1.07) 0.80 (0.61–1.04)
Men 7,831 0.58 (0.34–0.99) 0.55 (0.31–0.95) 0.52 (0.29–0.92)
Women 7,780 1.00 (0.74–1.34) 0.98 (0.73–1.33) 0.94 (0.69–1.28)
TDQ
Totald 15,608 0.90 (0.69–1.18) 0.88 (0.67–1.16) 0.87 (0.65–1.15)
Men 7,828 0.70 (0.41–1.20) 0.67 (0.38–1.16) 0.66 (0.37–1.17)
Women 7,780 1.03 (0.75–1.41) 1.01 (0.73–1.39) 0.97 (0.70–1.35)
HOT
Totald 15,604 0.80 (0.60–1.06) 0.78 (0.59–1.04) 0.75 (0.56–1.01)
Men 7,826 0.59 (0.33–1.05) 0.55 (0.30–0.99) 0.49 (0.26–0.92)
Women 7,778 0.92 (0.66–1.28) 0.91 (0.65–1.28) 0.88 (0.62–1.23)
HR, Hazard ratio; CI, Confidence interval; TDC, thyroid disorders (yes, no) classification based on a combination of medical questionnaire and medication
use; TDQ, thyroid disorders (yes, no) classification questionnaire based; HOT, hypothyroidism/struma (yes, no) classification based on thyroid hormone
use.
a adjusted for age and survey.
b adjusted for age, survey and lifestyle factors: education, smoking habits, physical activity, alcohol consumption, BMI, dietary pattern.
c adjusted for age, survey, lifestyle factors and clinical risk factors (hypertension, diabetes mellitus, hyperuricemia and unfavorable blood cholesterol ratio).
d additionally adjusted for sex in all models.
e n from lifestyle and clinical risk factor model.
doi:10.1371/journal.pone.0155499.t003
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thyroid disorders, especially treated hypothyroidism, regarding incident ICE was seen in men,
but not women. The findings were stable even after adjusting for lifestyle and clinical risk fac-
tors. However, to the best of our knowledge, no other study observed sex-differences regarding
this issue with a reduced risk for ICE only in men treated for thyroid disorders.
The major part of studies investigating the association between thyroid disorders and cere-
brovascular diseases used serum hormone concentrations (TSH and T4) for the classification
into diseased or healthy participants. Additionally, some of the studies collected information
about medication use or medical history and usually used this information to exclude partici-
pants suffering from thyroid disorders at baseline. Comparing our results (all study partici-
pants) with a recent meta-analysis adjusted for multiple confounders, they correspond to the
findings [12]. This meta-analysis included five prospective cohort studies and provided no evi-
dence for an increased risk of stroke associated with subclinical hypothyroidism [12]. Further-
more, in a Danish register-based retrospective cohort study no association between subclinical
or overt hypothyroidism and stroke was reported [17]. Contrary to these results, Qureshi et al.
found by examining the data from the 20-year follow-up of the First National Health and
Nutrition Survey those participants with hypothyroidism had a higher relative risk of all
strokes and of ischemic stroke [18]. In a recent meta-analysis including 17 prospective cohorts
with individual participant data of 47573 adults an increased risk of stroke events was found
among participants with subclinical hypothyroidism compared to euthyroidism in the age
groups 18–49 and 50–64 years, but not among participants aged 65–79 years and> = 80 years
[36]. In a Taiwanese study utilizing data from a hospital database and including 5793 hypothy-
roidism patients Yang et al. showed that hypothyroidism increased the risk for cerebrovascular
Table 4. Gender specific and overall hazard ratios (HR) and 95%CI for developing an ischemic cerebrovascular event (without embolic stroke)
according to thyroid disorders at baseline.
Crude modela Lifestyle modelb Lifestyle and clinical risk
factor modelc
HR (95%CI) HR (95%CI) HR (95%CI)
TDC ne
Totald 15,466 0.86 (0.65–1.14) 0.87 (0.65–1.15) 0.83 (0.62–1.11)
Men 7,749 0.54 (0.30–0.99) 0.55 (0.30–1.00) 0.51 (0.27–0.96)
Women 7,717 1.05 (0.76–1.46) 1.05 (0.75–1.46) 0.99 (0.71–1.40)
TDQ
Totald 15,463 0.93 (0.70–1.25) 0.94 (0.70–1.26) 0.91 (0.67–1.24)
Men 7,746 0.65 (0.36–1.19) 0.67 (0.37–1.22) 0.65 (0.35–1.23)
Women 7,717 1.11 (0.78–1.56) 1.10 (0.78–1.55) 1.04 (0.73–1.48)
HOT
Totald 15,460 0.77 (0.56–1.07) 0.78 (0.57–1.08) 0.74 (0.53–1.03)
Men 7,745 0.53 (0.27–1.02) 0.53 (0.27–1.03) 0.47 (0.23–0.94)
Women 7,715 0.92 (0.63–1.33) 0.92 (0.63–1.30) 0.88 (0.60–1.28)
HR, Hazard ratio; CI, Confidence interval; TDC, thyroid disorders (yes, no) classification based on a combination of medical questionnaire and medication
use; TDQ, thyroid disorders (yes, no) classification questionnaire based; HOT, hypothyroidism/struma (yes, no) classification based on thyroid hormone
use.
a adjusted for age and survey.
b adjusted for age, survey and lifestyle factors: education, smoking habits, physical activity, alcohol consumption, BMI, dietary pattern.
c adjusted for age, survey, lifestyle factors and clinical risk factors (hypertension, diabetes mellitus, hyperuricemia and unfavorable blood cholesterol ratio).
d additionally adjusted for sex in all models.
e n from lifestyle and clinical risk factor model
doi:10.1371/journal.pone.0155499.t004
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diseases (HR 1.89) [37]. However, if only blood levels are used it has be considered that the
classification (diseased versus healthy) was based on a single measurement, which itself
depends on factors such as circadian rhythm of TSH [38], diagnostic TSH assay variation,
respective TSH reference ranges [38], or drug intake (e.g. psychotropic drugs, thyroid hor-
mones) [39].
Utilizing data on medical interview data and information on medication use we computed
the variable thyroid disorder in three different ways: First by combination of interview data
about prevalent treated thyroid disorders, antithyroid medication use and thyroid hormone
use—TDC, second by medical anamnesis only—TDQ, and third by thyroid hormone use
only–HOT. For both the combined variable and the thyroid hormone use variable a signifi-
cantly reduced risk of ICE was seen in men only. To date, only a few studies exist, which focus
on the association between treated thyroid disorders and cerebrovascular diseases and only one
reported results comparable to ours. Contrary to our results, a Scottish study based on clinical
registry data focusing on patients treated for thyroid disorders, reported an increased risk of
cerebrovascular diseases in patients treated for hypothyroidism compared to the general popu-
lation [14]. A reason for these differences could be that the Scottish study could not adjust for
lifestyle factors such as smoking and BMI [14] which are associated with thyroid disorders and
stroke [40–43].
Our finding of a significantly reduced risk of ICE only in men with treated thyroid disorders
was unexpected. Beside gender differences in the etiology of hypothyroidism [44], one explana-
tory approach for the gender difference in our findings could be a gender-specific risk profile.
For example Yonemoto et al. [45] reported, that BMI as well as a combination of obesity and
diabetes were risk factors for ischemic stroke in men only.
Another possible explanation for the observed gender-specific association between treated
thyroid disorder and ICE could be the tendency of males to delay medical care until an
advanced or more noticeable stage of disease [46]. Thus, men not under treatment may more
often have an advanced stage of disease when they go to the doctor, which may leads to rarer
misdiagnosis and more often to adequate treatment. While our data may reflect regional pat-
tern, the under-treatment in males, reported from other European regions [47] seems not to
occur in our sample.
The strengths of our study are the prospective design, the large sample size drawn from the
general population and the variety of available data on lifestyle factors, health status, and
important clinical parameters, which allowed multiple adjustments to control for potential
confounding. The consistency of the results in the sensitivity analyses was quite reassuring.
However, there are also limitations which should be noted. The MONICA/KORA Augsburg
Cohort study was limited to men and women aged 25 to 74 years from the south of Germany,
thus caution is needed in generalizing our results to people of other populations and age-
ranges. Another limitation of our data was the self-reported nature of the medical history, with-
out verification. As described in the publication from Brix et al. 2001 the validity of self-
reported hypothyroidism and hyperthyroidism achieves a high sensitivity, but only moderate
specificity due to the high number of false-positive reports [48]. The utilization of the ATC
classification system avoids false positive disease reports. For this reason, we combined self-
reported diagnoses with medication use based on the ATC-code drug classification to get a
more reliable and not invasive information source. Nevertheless, the prevalences of thyroid
dysfunctions in our cohort were comparable to the findings in the existing literature confirm-
ing our method. At baseline examination, the prevalences of thyroid disorders ascertained with
medical interview questions and medication use (thyroid hormones and antithyroid medica-
tion) were about 3.5% in men and about 13.6% in women. In the existing literature the overall
prevalence for all types of thyroid disorders in northern Europe including Germany collected
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via questionnaire and medication use ranges from 1.5 to 8.3% in men and from 7.9 to 18.0% in
women[49]. With information from medication use the prevalence of HOT were 2.8% in men
and 12.3% in women. The Robert Koch Institute/Germany published slightly lower prevalence
rates for hypothyroidism/goiter based on medical history questions and thyroid hormone use
(1.6% in men, 8.1% in women) [49]. Two studies in Germany using serum parameter observed
prevalences of hypothyroidism depending on the study participant’s age between 2.2% and
13.9% in men and between 1.7% and 31.0% in women [50]. In the USA, large studies have
found prevalences of overt hypothyroidism (based on serum parameter) varying from 0.2–
1.4% and prevalences of subclinical hypothyroidism in the range of 3.8–13.9% for men and
women combined [51–53]. Irrespective of the underlying data source and varying serum blood
TSH and fT4 limits for classification, hypothyroidism is more common with advancing age
and in women [1, 49, 52]. This is confirmed by our results.
The absence of serum thyroid hormone data is also a limitation our analyses.
Despite the fact that we adjusted for a variety of variables, adjustment may be insufficient to
rule out residual confounding, potentially in men. Also competing risk could be an influencing
factor in the analyses. After exclusion of participants who had an ICE in the first two years, no
changes in the results were observed so that reverse causation could be ruled out. Thyroid dis-
orders are more common in women and cerebrovascular events more common in men, which
leads to a difference distribution of outcome and predictor variables between men and women
and to limited statistical power in the former. In addition, we had no data available on atrial
fibrillation for use as a co-variate and the number of individuals with hyperthyroidism was too
small in our study for meaningful statistical analyses.
Conclusion
In summary, we found that men from the general population treated for thyroid disorders had
a significantly reduced risk of ischemic cerebrovascular events compared to men without thy-
roid disorders. For the whole study population and women with treated thyroid disorder we
saw no association at all. These findings underline the importance of thyroid disorder treat-
ment. However, in the available literature results vary and further research examining thyroid
disorders and their treatment are requested. Further adequately powered studies using infor-
mation on blood hormone data, physician-diagnosed diseases and medication use, would be
helpful.
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